Medicinova (MNOV) 3.96 $MNOV
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS
GlobeNewswire - Tue Apr 21, 12:45PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigator, presented interim safety data from the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. There were no safety or tolerability concerns in the MN-166 (ibudilast) treatment group compared with the placebo treatment group after three months of treatment.
MNOV: 3.96 (-0.12)
How Energetic is Healthcare and How Healthy is The Energy Sector: Free Research on MediciNova, Cardica, Rosetta Genomics, Gulf Port Energy, Matador Resources
PR Newswire - Tue Apr 21, 9:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ROSG: 3.83 (-0.20), MNOV: 3.96 (-0.12), CRDC: 0.44 (+0.01), MTDR: 26.96 (+0.53), GPOR: 49.00 (-0.49)
MediciNova Gets Fast Tracked Into Thick Of NASH Race
Clinically Sound Investor - at Seeking Alpha - Thu Apr 16, 3:29PM CDT
MNOV: 3.96 (-0.12)
MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation
at The Street - Thu Apr 16, 1:21PM CDT
MedicNova (MNOV) shares are climbing after its drug received fast track status from the Food and Drug Administration.
MNOV: 3.96 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:45AM CDT
NPD: 2.87 (+0.25), INVE: 10.16 (-0.48), MNOV: 3.96 (-0.12), NHTC: 21.52 (+1.57), BSPM: 1.45 (-0.05), ANY: 3.33 (-0.16), TZOO: 13.06 (-0.02), FNRG: 3.11 (-0.86), RLJE: 1.06 (-0.01), PRTY: 20.65 (-0.22), PTX: 7.44 (-0.05), RCPI: 3.05 (+0.03), CHOP: 3.67 (-0.26), NVGN: 7.40 (-0.30), ETSY: 25.12 (-0.63), NFLX: 557.68 (-2.76), ENZN: 1.70 (+0.20), INUV: 2.32 (-0.05), GLF: 13.77 (-0.11), PCRX: 83.61 (-0.41)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:12AM CDT
NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), INVE: 10.16 (-0.48), SNTA: 2.97 (+0.01), MNOV: 3.96 (-0.12), TZOO: 13.06 (-0.02), PNRA: 181.59 (-2.26), CLRX: 0.95 (unch), REN: 1.36 (-0.06), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), NVGN: 7.40 (-0.30), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), SNDK: 68.48 (+0.56)
MediciNova up 42% premarket on Fast Track status for NASH candidate
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:05AM CDT
MNOV: 3.96 (-0.12)
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan
GlobeNewswire - Thu Apr 16, 7:30AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that the Tokyo Stock Exchange (TSE) has announced a new rule affecting the trading of dual-listed stocks on the Tokyo Stock Exchange, including the stock of MediciNova. Under the old rule, the TSE had used the previous day's closing price of MediciNova's stock on the TSE as the base price to determine the daily limit of the stock price movement on the TSE (also known as the "circuit breaker" rule). Under the new rule that will become effective on April 20, 2015, if (1) the difference between the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen and the previous day's closing price of MediciNova's stock on the TSE ("the price divergence"
is greater than the daily limit of the stock price movement on the TSE and (2) the price divergence is greater than 20%, then the TSE will use the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen as the base price to determine the daily limit of the stock price movement on the TSE.
MNOV: 3.96 (-0.12)
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis
GlobeNewswire - Thu Apr 16, 7:05AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 3.96 (-0.12)
MediciNova reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:05AM CDT
MNOV: 3.96 (-0.12)
MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona
GlobeNewswire - Mon Mar 02, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova's ongoing Phase 2a clinical trial of MN-166 (ibudilast) in opioid dependence has been selected for presentation at the 77 Annual Meeting of the College on Problems of Drug Dependence (CPDD) to be held June 13-18, 2015 in Phoenix, Arizona. The results will be presented by Dr. Verena Metz of the New York State Psychiatric Hospital (NYSPI) at Columbia University.
MNOV: 3.96 (-0.12)
MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS
GlobeNewswire - Mon Feb 16, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has enrolled 30 of the 60 subjects planned for participation.
MNOV: 3.96 (-0.12)
MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF
GlobeNewswire - Tue Feb 10, 8:07AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that FDA (U.S. Food and Drug Administration) has approved the protocol for a clinical trial of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis). Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical trial of MN-001 in IPF. The IPF protocol was filed under MediciNova's open IND (Investigational New Drug Application) in FDA's Division of Pulmonary, Allergy, and Rheumatology Products (DPARP). FDA has granted orphan-drug designation to MN-001 for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if MN-001 is approved for IPF.
MNOV: 3.96 (-0.12)
MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office
M2 - Wed Feb 04, 5:23AM CST
Biopharmaceutical company
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS
GlobeNewswire - Tue Apr 21, 12:45PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigator, presented interim safety data from the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. There were no safety or tolerability concerns in the MN-166 (ibudilast) treatment group compared with the placebo treatment group after three months of treatment.
MNOV: 3.96 (-0.12)
How Energetic is Healthcare and How Healthy is The Energy Sector: Free Research on MediciNova, Cardica, Rosetta Genomics, Gulf Port Energy, Matador Resources
PR Newswire - Tue Apr 21, 9:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ROSG: 3.83 (-0.20), MNOV: 3.96 (-0.12), CRDC: 0.44 (+0.01), MTDR: 26.96 (+0.53), GPOR: 49.00 (-0.49)
MediciNova Gets Fast Tracked Into Thick Of NASH Race
Clinically Sound Investor - at Seeking Alpha - Thu Apr 16, 3:29PM CDT
MNOV: 3.96 (-0.12)
MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation
at The Street - Thu Apr 16, 1:21PM CDT
MedicNova (MNOV) shares are climbing after its drug received fast track status from the Food and Drug Administration.
MNOV: 3.96 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:45AM CDT
NPD: 2.87 (+0.25), INVE: 10.16 (-0.48), MNOV: 3.96 (-0.12), NHTC: 21.52 (+1.57), BSPM: 1.45 (-0.05), ANY: 3.33 (-0.16), TZOO: 13.06 (-0.02), FNRG: 3.11 (-0.86), RLJE: 1.06 (-0.01), PRTY: 20.65 (-0.22), PTX: 7.44 (-0.05), RCPI: 3.05 (+0.03), CHOP: 3.67 (-0.26), NVGN: 7.40 (-0.30), ETSY: 25.12 (-0.63), NFLX: 557.68 (-2.76), ENZN: 1.70 (+0.20), INUV: 2.32 (-0.05), GLF: 13.77 (-0.11), PCRX: 83.61 (-0.41)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:12AM CDT
NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), INVE: 10.16 (-0.48), SNTA: 2.97 (+0.01), MNOV: 3.96 (-0.12), TZOO: 13.06 (-0.02), PNRA: 181.59 (-2.26), CLRX: 0.95 (unch), REN: 1.36 (-0.06), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), NVGN: 7.40 (-0.30), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), SNDK: 68.48 (+0.56)
MediciNova up 42% premarket on Fast Track status for NASH candidate
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:05AM CDT
MNOV: 3.96 (-0.12)
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan
GlobeNewswire - Thu Apr 16, 7:30AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that the Tokyo Stock Exchange (TSE) has announced a new rule affecting the trading of dual-listed stocks on the Tokyo Stock Exchange, including the stock of MediciNova. Under the old rule, the TSE had used the previous day's closing price of MediciNova's stock on the TSE as the base price to determine the daily limit of the stock price movement on the TSE (also known as the "circuit breaker" rule). Under the new rule that will become effective on April 20, 2015, if (1) the difference between the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen and the previous day's closing price of MediciNova's stock on the TSE ("the price divergence"
is greater than the daily limit of the stock price movement on the TSE and (2) the price divergence is greater than 20%, then the TSE will use the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen as the base price to determine the daily limit of the stock price movement on the TSE. MNOV: 3.96 (-0.12)
FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis
GlobeNewswire - Thu Apr 16, 7:05AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 3.96 (-0.12)
MediciNova reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:05AM CDT
MNOV: 3.96 (-0.12)
MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona
GlobeNewswire - Mon Mar 02, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova's ongoing Phase 2a clinical trial of MN-166 (ibudilast) in opioid dependence has been selected for presentation at the 77 Annual Meeting of the College on Problems of Drug Dependence (CPDD) to be held June 13-18, 2015 in Phoenix, Arizona. The results will be presented by Dr. Verena Metz of the New York State Psychiatric Hospital (NYSPI) at Columbia University.
MNOV: 3.96 (-0.12)
MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS
GlobeNewswire - Mon Feb 16, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has enrolled 30 of the 60 subjects planned for participation.
MNOV: 3.96 (-0.12)
MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF
GlobeNewswire - Tue Feb 10, 8:07AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that FDA (U.S. Food and Drug Administration) has approved the protocol for a clinical trial of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis). Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical trial of MN-001 in IPF. The IPF protocol was filed under MediciNova's open IND (Investigational New Drug Application) in FDA's Division of Pulmonary, Allergy, and Rheumatology Products (DPARP). FDA has granted orphan-drug designation to MN-001 for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if MN-001 is approved for IPF.
MNOV: 3.96 (-0.12)
MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office
M2 - Wed Feb 04, 5:23AM CST
Biopharmaceutical company
